For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 18,011 | |||
| General and administrative | 8,737 | |||
| Total operating expenses | 26,748 | |||
| Loss from operations | -26,748 | |||
| Interest income | 1,375 | |||
| Other income (expense), net | 7,159 | |||
| Net loss | -18,214 | |||
| Unrealized gain on short-term investments | 8 | |||
| Comprehensive loss | -18,206 | |||
| Basic EPS | -2.46 | |||
| Diluted EPS | -3.26 | |||
| Basic Average Shares | 7,419,060 | |||
| Diluted Average Shares | 7,783,182 | |||
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)